In PAH for example, it has been suggested that G protein-biased agonists, which avoid β-arrestin dependent internalisation, would help maintain the apelin receptor target at the cell surface and prolong increases in vasodilatation and cardiac output induced by therapeutic agents (36, 51). Here, APLNR is linked to pulmonary arterial hypertension.